Merck is buying Prometheus for 11 billion
Prometheus has a promising immunology drug that treats ulcerative colitis and Crohn's disease currently in phase 2 trials.
Basically similar to our 761 that's been in preclinical development for many years and might go into humans in 2024.
It's been a mystery to many IMM shareholders just why it's taken an ice age to get this very promising drug into the clinic and especially as pre-clinical animal studies was safe, well tolerated and good early signs of efficacy
Many thought it would be fast tracked due to unmet need and it addresses the cause as opposed to current treatments only helping with symptoms.
Maybe - just maybe Merck has flagged it's only interest is Efti due to above acquisition (which has been on the radar for over a year - see Prometheus share price history). 761 could be a potential competitor and if I was Marc, I would be comfortable shelving 761 - for the time-being if a deal is on the cards with Merck.
Pure speculation of course
Merck is buying Prometheus for 11 billionPrometheus has a...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |